Drugs / HPN536
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03872206 | Apr 2019 → Jan 2023 | — | Harpoon Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPN536 | “We designed HPN536, a 53-kDa, trispecific, T-cell-activating protein-based construct, which binds to MSLN-expressing tumor cells, CD3ε on T cells, and to serum albumin.” PMID 33262134 ↗ Dec 2020 |
| Action | Deplete | “leading to T-cell activation and potent redirected target cell lysis” PMID 33262134 ↗ Dec 2020 |
| Modality | Protein / enzyme biologic | “a 53-kDa, trispecific, T-cell-activating protein-based construct” PMID 33262134 ↗ Dec 2020 |
| Route | Intravenous | “HPN536 administered once weekly via IV infusion” NCT03872206 ↗ |
| Target | MSLN | “which binds to MSLN-expressing tumor cells” PMID 33262134 ↗ Dec 2020 |